Celgene sues Dr Reddy’s over Pomalyst generic

Celgene has filed a lawsuit against Indian drugs manufacturer Dr Reddy’s Laboratories (DRL) to halt its plan to produce and market generic versions of Pomalyst (pomalidomide)—Celgene’s multiple myeloma treatment.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Celgene, Dr Reddy's abandon cancer drug patent dispute

1 February 2022 Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.

Big Pharma

Dr Reddy’s to receive $72m in Suboxone settlement

27 June 2022 India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone sublingual film.

Americas

Lawsuit against Celgene, BMS and others moves forward

25 April 2023 New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.

More on this story

Americas

Celgene, Dr Reddy's abandon cancer drug patent dispute

1 February 2022 Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.

Big Pharma

Dr Reddy’s to receive $72m in Suboxone settlement

27 June 2022 India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone sublingual film.

Americas

Lawsuit against Celgene, BMS and others moves forward

25 April 2023 New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.

More on this story

Americas

Celgene, Dr Reddy's abandon cancer drug patent dispute

1 February 2022 Bristol-Myers Squibb subsidiary, Celgene has settled its lawsuit against India-based drug maker Dr Reddy's over a generic version of the blockbuster cancer treatment, Pomalyst.

Big Pharma

Dr Reddy’s to receive $72m in Suboxone settlement

27 June 2022 India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone sublingual film.

Americas

Lawsuit against Celgene, BMS and others moves forward

25 April 2023 New Jersey judge denies motion to stay antitrust action regarding blockbuster cancer drug | Defendants had argued litigation would be unnecessary and costly.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

Celgene sues Dr Reddy’s over Pomalyst generic

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features